Janus-faced amiodarone-induced pneumopathy

Pulmonology. 2020 Mar-Apr;26(2):101-103. doi: 10.1016/j.pulmoe.2019.07.003. Epub 2019 Aug 3.

Authors

S Cerri¹, R Tonelli¹, P Faverio², N Sverzellati³, E Clini⁴, F Luppi²

Affiliations

¹ Center for Rare Lung Diseases, Respiratory Disease Unit, University Hospital of Modena and University of Modena and Reggio Emilia, Modena, Italy.
² Respiratory Unit, University of Milano Bicocca, S. Gerardo Hospital, Monza, Italy.
³ Section of Radiology, Unit of Surgical Sciences, Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy.
⁴ Center for Rare Lung Diseases, Respiratory Disease Unit, University Hospital of Modena and University of Modena and Reggio Emilia, Modena, Italy. Electronic address: [email protected].

PMID: 31387801
DOI: 10.1016/j.pulmoe.2019.07.003

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Amiodarone / adverse effects*
Amiodarone / therapeutic use
Anti-Arrhythmia Agents / adverse effects*
Anti-Arrhythmia Agents / therapeutic use
Atrial Fibrillation / drug therapy*
Bronchoalveolar Lavage / methods
Drug Therapy, Combination
Factor Xa Inhibitors / administration & dosage
Factor Xa Inhibitors / therapeutic use
Glucocorticoids / administration & dosage
Glucocorticoids / therapeutic use
Humans
Male
Prednisone / administration & dosage
Prednisone / therapeutic use
Pulmonary Fibrosis / chemically induced*
Pulmonary Fibrosis / diagnostic imaging
Pulmonary Fibrosis / drug therapy
Pulmonary Fibrosis / pathology
Tomography, X-Ray Computed / methods
Treatment Outcome
Withholding Treatment

Substances

Anti-Arrhythmia Agents
Factor Xa Inhibitors
Glucocorticoids
Amiodarone
Prednisone